Depo-Provera Meningioma Surgery in 2026: Resection, Radiosurgery, or Watching and Waiting — the Decision Women Face Now
A meningioma found after years on Depo-Provera does not automatically mean brain surgery. About half of incidental meningiomas begin with active monitoring, roughly a quarter go straight to surgery, and the rest receive focused radiation — and the right path depends on the tumor’s size, symptoms, location, and grade, not on the diagnosis alone.
Key facts
- A September 2025 JAMA study of more than 10 million US women found that Depo-Provera (DMPA) use for more than 4 years, or started after age 31, carried a relative risk of 2.43 for meningioma compared with no contraception.
- The absolute risk remains low: the same study’s number needed to harm was 1,152, meaning 1,152 women treated with DMPA for one additional meningioma.
- A 2019 meta-analysis of incidental meningiomas found initial management was active monitoring in 50.7%, surgery in 27.3%, and stereotactic radiosurgery in 22.0% of cases.
- Even after complete surgical removal, meningioma recurs within 15 years about 30% of the time, which is why follow-up imaging continues for years.
- About 94.0% of operated meningiomas in that meta-analysis were WHO grade I, the slowest-growing grade.
What a Meningioma Is — and Why “Benign” Does Not Mean Harmless
A meningioma is a tumor that grows from the meninges, the protective layers surrounding the brain and spinal cord. It is the most common tumor of the head, and it occurs about three times more often in women than in men. Most meningiomas are benign, meaning they do not spread to distant parts of the body the way a cancer metastasizes.
Benign, however, is not the same as harmless. A slow-growing tumor inside a closed skull can press on the brain, causing headache, seizures, weakness, vision changes, or personality change, depending on where it sits. Size and location therefore drive most treatment decisions.
Doctors grade meningiomas under the World Health Organization (WHO) system: grade I tumors grow slowly and are most common; grade II (atypical) tumors grow faster and recur more often; grade III (malignant) tumors are rare and aggressive. The grade is usually confirmed only after tissue is examined.
The Depo-Provera Link: What the 2025 Study Actually Found
Depo-Provera is the brand name for depot medroxyprogesterone acetate (DMPA), an injectable progestin contraceptive given every three months. Concern about DMPA and meningioma grew from a French case-control study published in the BMJ in 2024, and sharpened in September 2025, when JAMA published a retrospective study of more than ten million US women on hormonal birth control.
The JAMA study found that women who had used DMPA for more than four years, or who started DMPA after age 31, were more than twice as likely to develop a meningioma as women who used no contraception, a relative risk of 2.43. No increased risk was found for any other US contraceptive in the study, including combined oral contraceptives, progestin-only pills, and levonorgestrel IUDs.
Two cautions keep that finding honest. Correlation does not prove causation: an association in records is not proof the drug caused a particular woman’s tumor. And the absolute risk is small — with a number needed to harm of 1,152, most long-term DMPA users never develop a meningioma. The study changes how doctors counsel and monitor; it does not rewrite any individual diagnosis. See also our account of the meningioma science and who qualifies.
The Three Paths: Surgery, Radiosurgery, or Active Monitoring
There is no single consensus on the best management for an incidental meningioma, and the numbers show it. In a 2019 systematic review and meta-analysis of incidental intracranial meningiomas, half of patients (50.7%) began with active monitoring, 27.3% went directly to surgery, and 22.0% received stereotactic radiosurgery. Active monitoring is not neglect: it means scheduled MRI scans and clinic visits, with treatment if the tumor grows or symptoms appear.
Monitoring is often the first choice for a small, silent tumor, especially when surgery would risk nearby critical structures. About a quarter of monitored patients (24.8%) eventually received an intervention, after a weighted mean of 24.8 months — monitoring is a decision with a calendar, not an open-ended shrug. A tumor that grows or presses on vision, speech, or movement usually moves the plan toward treatment.
Surgery is usually first when a tumor is large, symptomatic, or growing, or when tissue is needed to establish the grade. Radiosurgery — a single highly focused radiation dose, often Gamma Knife — suits some smaller tumors where open surgery is risky. Each path trades one set of risks for another; the honest conversation is which trade fits this tumor and this patient.
What Surgery Really Involves — and What It Cannot Promise
Surgical excision of a meningioma usually means a craniotomy: the surgeon opens the skull, removes the tumor, and, where safely possible, the involved dura and bone. Neurosurgeons describe the extent of removal carefully, because it predicts recurrence. A gross total resection removes all visible tumor; a subtotal resection leaves some behind, usually because it clings to a nerve, vessel, or brainstem where further removal would cause harm.
Recurrence follows grade and completeness. Reported five-year recurrence rates are roughly 5 to 25% for WHO grade I, 30 to 50% for grade II, and 50 to 94% for grade III tumors. Even after complete removal, meningioma recurs within 15 years about 30% of the time, which is why surveillance scans continue long after a successful operation. A second recurrence peak seven to ten years after subtotal resection has been reported in long-term follow-up studies.
Surgery carries its own risks: the 2019 meta-analysis reported pooled morbidity of 11.8% after surgery, blending minor and major complications across centers and definitions, so your surgeon’s own record for tumors like yours matters more than any average. Infection, bleeding, seizure, stroke, and new neurological deficit are all possible, and recovery ranges from weeks to months.
When Radiosurgery Fits — and When It Does Not
Stereotactic radiosurgery is not surgery in the everyday sense: no incision, no removed tissue, and no pathology result afterward. A focused beam treats the tumor in one session or a few fractions, and the tumor typically stops growing or shrinks slowly over months to years. It is often chosen for small tumors, for tumors near the skull base or optic nerves, for patients whose health makes open surgery risky, and for regrowth after a previous resection.
The trade-offs are different, not absent. Radiosurgery cannot relieve pressure quickly, so it is a poor choice for a large tumor already causing dangerous swelling. It provides no tissue for grading, and radiation effects can appear months later. The same meta-analysis reported pooled morbidity of 32.0% after radiosurgery, a strikingly high figure reflecting broad definitions and older series; a center’s current results should guide you, not a pooled average.
For atypical (grade II) meningiomas after complete resection, the ROAM/EORTC-1308 phase 3 trial randomized 157 patients to radiotherapy over 30 sessions or observation. Until such trials settle the balance, immediate radiation versus watchful waiting after a grade II resection remains a judgment call, best made with surgeon and radiation oncologist together.
Who Benefits From This — and Who Does Not
This guide helps most directly women who used Depo-Provera for years and now face a meningioma diagnosis, and their families. If your tumor is small and silent, the monitoring figures above give you a realistic picture of what watchful waiting looks like — and when it ends. If your tumor is symptomatic or growing, the surgery and radiosurgery sections give you the questions to ask before consenting: extent of resection, grade, recurrence odds, and the center’s own complication rates.
It also helps women deciding about contraception after a family meningioma scare, and anyone gathering records for a claim: grade, extent of resection, and imaging history are the three facts every later decision uses. Our timeline guide to diagnosis, records, and filing deadlines covers that paper trail.
It does not help everyone equally. Women whose meningioma was found incidentally, is tiny, and has been stable for years may need nothing more than continued scans, and this article should not push them toward treatment. Women with a grade III tumor, or a tumor already causing severe symptoms, face urgent decisions that no general guide can settle. And women who never used DMPA will find the drug link irrelevant to their case, even though the surgery-versus-monitoring framework still applies to any meningioma.
The Records and Decisions That Protect Both Your Health and Any Claim
First, settle the contraception question with your doctor promptly, and do not stop or switch on the basis of an article. Stopping DMPA weighs pregnancy risk, bone density, and bleeding against an uncertain tumor benefit, and no study promises an existing meningioma shrinks when the drug stops. Insist on a documented plan: the next scan date, the growth threshold that triggers treatment, and the symptoms that warrant urgent care.
Second, keep a complete file: every MRI report and image disc, the operative report stating the extent of resection, the pathology report stating the WHO grade, and the radiation plan if one is given. These four documents decide almost every later question. Ask for copies at each step rather than reconstructing them years later.
Third, get a second opinion from a center that treats many meningiomas before a major operation, and ask for its own numbers: how often it achieves gross total resection for tumors in your location, and its complication rate. Finally, if you are considering a claim, speak to an attorney early: deadlines vary by state and by discovery date, and a monitoring plan does not pause them. For the broader picture of Depo-Provera harms beyond meningioma, including the bone-density warning, see our guide to bone density loss and the black-box warning.
For more context on how our channel covers health and money topics, visit the Problem Solved channel.
Frequently asked questions
Who benefits most from reading a surgery-versus-monitoring guide like this?
Women with a meningioma after long-term Depo-Provera use who must choose between surgery, radiosurgery, and monitoring, and families helping them weigh recurrence odds against treatment risks.
Who does this guide not help, or who should not rely on it?
Women with an urgent, symptomatic, or grade III tumor need immediate specialist decisions, not a general guide; women with a tiny stable tumor may need only continued scans; and women who never used DMPA will find the drug discussion irrelevant to their case.
How do I start making the treatment decision?
Ask your neurosurgeon for four facts in writing: the tumor’s size, location, and symptoms; the planned extent of resection and its risks; the expected WHO grade pathway; and the scan schedule and growth threshold that would trigger treatment. Then get a second opinion from a high-volume meningioma center before consenting to major surgery.
If I stop Depo-Provera, will my meningioma shrink?
No study promises that. Some hormone-related meningiomas are watched after stopping a progestin, but shrinkage is not established for DMPA, and stopping carries its own risks, including pregnancy. Decide with your doctor, and let follow-up imaging — not hope — show what the tumor does.
Do I need surgery if my meningioma causes no symptoms?
Not necessarily. About half of incidental meningiomas in the 2019 meta-analysis began with active monitoring, and only about a quarter of monitored patients later needed intervention. Small, silent, stable tumors are often watched; growth or new symptoms usually change the plan.
Can I still pursue a claim if I choose monitoring instead of surgery?
Choosing monitoring does not by itself end a legal question, but deadlines vary by state and by when the link was discovered, so speak to a qualified attorney promptly rather than assuming the clock waits for treatment. Keep every scan, report, and prescription record in the meantime.
This article is general information only, not medical or legal advice. Treatment decisions belong to you and your doctors; any legal question belongs to a qualified attorney in your state.